93 related articles for article (PubMed ID: 24453570)
21. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
22. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
Krentz HB; Auld MC; Gill MJ;
CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
[TBL] [Abstract][Full Text] [Related]
23. Clinical and economic burden of intravenous paclitaxel or nab-paclitaxel for metastatic breast cancer.
Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP30-SP36. PubMed ID: 33395242
[TBL] [Abstract][Full Text] [Related]
24. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
25. Assessing the economic burden of breast cancer in a US managed care population.
Barron JJ; Quimbo R; Nikam PT; Amonkar MM
Breast Cancer Res Treat; 2008 May; 109(2):367-77. PubMed ID: 17674201
[TBL] [Abstract][Full Text] [Related]
26. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
27. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
Leuk Res; 2018 Aug; 71():27-33. PubMed ID: 29944984
[TBL] [Abstract][Full Text] [Related]
28. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
29. Costs associated with febrile neutropenia in the US.
Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
[TBL] [Abstract][Full Text] [Related]
30. The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Subramanian J; Fernandes AW; Laliberté F; Pavilack M; DerSarkissian M; Duh MS
Lung Cancer; 2019 Dec; 138():131-138. PubMed ID: 31733614
[TBL] [Abstract][Full Text] [Related]
31. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.
Bell JA; Galaznik A; Blazer M; Shih HC; Farrelly E; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV
Pharmacoecon Open; 2019 Jun; 3(2):237-245. PubMed ID: 30324565
[TBL] [Abstract][Full Text] [Related]
32. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab.
Knight T; Bond TC; Popelar B; Wang L; Niewoehner JW; Anastassopoulos K; Philbin M
Clinicoecon Outcomes Res; 2017; 9():271-279. PubMed ID: 28553129
[TBL] [Abstract][Full Text] [Related]
33. Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Qin A; Oster G
BMC Cancer; 2011 Jun; 11():250. PubMed ID: 21676243
[TBL] [Abstract][Full Text] [Related]
34. Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study.
Perrier M; Polazzi S; Lemelin A; Fernandez V; Labonne S; Maucort-Boulch D; Lombard-Bohas C; Duclos A; Walter T
J Neuroendocrinol; 2022 Apr; 34(4):e13092. PubMed ID: 35078272
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel.
Brady BL; Lucci M; Wilson K; Fox KM; Wojtynek J; Cooper C; Varker H; Chebili CL; Dokubo I
Am J Manag Care; 2021 Jan; 27(1 Spec. No.):SP37-SP43. PubMed ID: 33395243
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.
Vekeman F; Cloutier M; Yermakov S; Amonkar MM; Arondekar B; Duh MS
Melanoma Res; 2014 Dec; 24(6):602-10. PubMed ID: 24926818
[TBL] [Abstract][Full Text] [Related]
37. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
38. Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Mehra M; Wu Y; Dhawan R
J Med Econ; 2012; 15(5):836-43. PubMed ID: 22463616
[TBL] [Abstract][Full Text] [Related]
39. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
Kawachi I; Okamoto S; Sakamoto M; Ohta H; Nakamura Y; Iwasaki K; Yoshida M; Hiroi S; Ogino M
BMC Neurol; 2019 Dec; 19(1):324. PubMed ID: 31842786
[TBL] [Abstract][Full Text] [Related]
40. The economic impact of disease progression and death in hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients: using Korean nationwide health insurance claims data.
Park SK; Park JA; Yang SY; Shin JY; Koh H
Curr Med Res Opin; 2020 Nov; 36(11):1825-1833. PubMed ID: 32965131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
